Literature DB >> 11244376

Insight and resistance in patients with obsessive-compulsive disorder.

F Catapano1, R Sperandeo, F Perris, M Lanzaro, M Maj.   

Abstract

The aim of this study was to evaluate the degree of insight and resistance in a sample of obsessive-compulsive patients, and the predictive value of poor insight with respect to response to treatment with serotonin reuptake inhibitors (SRIs). Ninety-three patients fulfilling DSM-IV criteria for obsessive-compulsive disorder were evaluated. Seventy patients were treated with an SRI in a 24-week open-label trial. Sixteen percent of the patients did not recognize obsessions and compulsions as unreasonable or senseless. Fifty-two percent of the patients did not try to resist, 72% had little or no control over obsessions, and 64% were not able to exercise an effective control over compulsions. Patients with poor insight had a greater severity of obsessive-compulsive symptoms, a higher rate of schizophrenia spectrum disorders in their first-degree relatives and a higher frequency of a history of psychiatric disorders during childhood. Fifty-two percent of the patients with normal insight responded to SRIs, whereas none of the patients with poor insight were found to be responders. These results suggest the utility of the assessment of insight and resistance in obsessive-compulsive patients, also for the prediction of response to treatment with SRIs. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11244376     DOI: 10.1159/000049282

Source DB:  PubMed          Journal:  Psychopathology        ISSN: 0254-4962            Impact factor:   1.944


  17 in total

1.  Understudied clinical dimensions in pediatric obsessive compulsive disorder.

Authors:  Adam B Lewin; Nicole Caporino; Tanya K Murphy; Gary R Geffken; Eric A Storch
Journal:  Child Psychiatry Hum Dev       Date:  2010-12

2.  Dimensional correlates of poor insight in obsessive-compulsive disorder.

Authors:  Ewgeni Jakubovski; Christopher Pittenger; Albina Rodrigues Torres; Leonardo Franklin Fontenelle; Maria Conceicao do Rosario; Ygor Arzeno Ferrão; Maria Alice de Mathis; Euripedes Constantino Miguel; Michael H Bloch
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-05-27       Impact factor: 5.067

3.  Factors Associated with Depression in Obsessive-Compulsive Disorder: A Cross-Sectional Study.

Authors:  Ebru Altintaş; Nilgün Taşkintuna
Journal:  Noro Psikiyatr Ars       Date:  2015-12-01       Impact factor: 1.339

Review 4.  Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment.

Authors:  Michael Poyurovsky; Abraham Weizman; Ronit Weizman
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

5.  Correlates of insight among youth with obsessive-compulsive disorder.

Authors:  Adam B Lewin; R Lindsey Bergman; Tara S Peris; Susanna Chang; James T McCracken; John Piacentini
Journal:  J Child Psychol Psychiatry       Date:  2009-12-17       Impact factor: 8.982

Review 6.  Pharmacotherapeutic Strategies and New Targets in OCD.

Authors:  Christopher Pittenger
Journal:  Curr Top Behav Neurosci       Date:  2021

7.  Obsessive compulsive disorder masquerading as psychosis.

Authors:  Dhanya Raveendranathan; Lakshmi Shiva; Eesha Sharma; Ganesan Venkatasubramanian; Mukund G Rao; Shivarama Varambally; Bangalore N Gangadhar
Journal:  Indian J Psychol Med       Date:  2012-04

8.  Current management of obsessive and phobic states.

Authors:  Serena Goljevscek; Livia A Carvalho
Journal:  Neuropsychiatr Dis Treat       Date:  2011-09-30       Impact factor: 2.570

Review 9.  Evidence-Based Assessment of Obsessive-Compulsive Disorder.

Authors:  Amy M Rapp; R Lindsay Bergman; John Piacentini; Joseph F McGuire
Journal:  J Cent Nerv Syst Dis       Date:  2016-08-21

10.  Dissociable source-monitoring impairments in obsessive-compulsive disorder and schizophrenia.

Authors:  Layla Lavallé; Rémy Bation; Clément Dondé; Marine Mondino; Jérome Brunelin
Journal:  Eur Psychiatry       Date:  2020-05-14       Impact factor: 5.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.